Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

Stopped early

Conditions studied: Keratoconus, Ectasia, Degeneration

In brief

To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication

Key facts

Study ID

NCT01097447

Run by

Cxlusa

People needed

2619

Starts

2009-12-01

Expected to finish

2017-04-30

Last updated by the study team

2018-10-11

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 8 years of age or older
• Diagnosis of keratoconus, post-LASIK ectasia, or pellucid marginal degeneration or forme fruste pellucid marginal degeneration.
• Diagnosis of FFKC
• History of Radial Keratotomy with fluctuating vision.
• Ability to provide written informed consent
• Likely to complete all study visits
• Minimum corneal thickness of at least 300 measured by ultrasound or Pentacam

You may not qualify if…

• Severe corneal scarring that markedly affects vision
• Contraindications to any study medications or their components
• Pregnancy or breast feeding
• Active Herpes Corneal Disease

Where it is running

• Clear View Eye & Laser Medical Center — San Diego, California, United States
• Corneal Consultants of Colorado, P.C — Littleton, Colorado, United States
• Chicago Cornea Consultants, LTD — Hoffman Estates, Illinois, United States
• Minnesota Eye Consultants, P.A. — Bloomington, Minnesota, United States
• Cornea Associates of Texas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.